- Home
- KBR vs DYN Comparison
KBR vs DYN Comparison
Compare KBR & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KBR | DYN |
|---|---|---|
| Founded | 1901 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.9B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KBR | DYN |
|---|---|---|
| Price | $35.78 | $23.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $52.43 | $37.00 |
| AVG Volume (30 Days) | 1.9M | ★ 2.4M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.83% | N/A |
| EPS Growth | ★ 15.05 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $5,767,000,000.00 | N/A |
| Revenue This Year | $4.56 | N/A |
| Revenue Next Year | $5.11 | N/A |
| P/E Ratio | $44.80 | ★ N/A |
| Revenue Growth | ★ 2.27 | N/A |
| 52 Week Low | $29.94 | $8.25 |
| 52 Week High | $52.23 | $25.00 |
Technical Indicators
Market Signals| Indicator | KBR | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 55.29 | 60.66 |
| Support Level | $35.52 | $16.47 |
| Resistance Level | $36.68 | $24.48 |
| Average True Range (ATR) | 1.13 | 1.22 |
| MACD | 0.25 | 0.22 |
| Stochastic Oscillator | 65.47 | 57.02 |
Price Performance
Historical ComparisonAbout KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is a global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: mission technology solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 36,000 people. The firm generated $7.8 billion in revenue in 2025.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.